At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PNT POINT BIOPHARMA GLOBAL INC
Halted 11-29 10:17:15 EST
12.50
+0.00
0.00%
High12.50
Low12.50
Vol0.00
Open12.50
D1 Closing12.50
Amplitude0.00%
Mkt Cap1.33B
Tradable Cap875.41M
Total Shares106.57M
T/O41.13M
T/O Rate0.00%
Tradable Shares70.03M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
NextNav Co-Founder and CTO Arun Raghupathy Receives Distinguished Alumni Award from University of Maryland’s Department of Electrical and Computer Engineering
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.